(Swissmedic) Moderna stock closed up more than 17% on Monday following news that its Covid-19 vaccine has been approved by Swissmedic for use in teens between 12 to 17 years.
Swissmedic found Moderna’s vaccine effective against symptomatic disease at about 93% after the second dose.
The study on vaccine efficacy involved 3,732 children within the age of 12 to 17 years.
MRNA: NASDAQ is up +2.65%.
